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Oral rotavirus vaccinea b s t r a c t
Background: Oral rotavirus vaccine (RVV) immunogenicity is considerably lower in low- versus high-
income populations; however, the mechanisms underlying this remain unclear. Previous evidence sug-
gests that the gut microbiota may contribute to differences in oral vaccine efficacy.
Methods: We performed whole metagenome shotgun sequencing on stool samples and measured anti-
rotavirus immunoglobulin A in plasma samples from a subset of infants enrolled in a cluster randomized
2  2 factorial trial of improved water, sanitation and hygiene and infant feeding in rural Zimbabwe
(SHINE trial: NCT01824940). We examined taxonomic microbiome composition and functional metagen-
ome features using random forest models, differential abundance testing and regression analyses to
explored associations with RVV immunogenicity.
Results: Among 158 infants with stool samples and anti-rotavirus IgA titres, 34 were RVV seroconverters.
The median age at stool collection was 43 days (IQR: 35–68), corresponding to a median of 4 days before
the first RVV dose. The infant microbiome was dominated by Bifidobacterium longum. The gut microbiome
differed significantly between early (42 days) and later samples (>42 days) however, we observed no
meaningful differences in alpha diversity, beta diversity, species composition or functional metagenomic
features by RVV seroconversion status. Bacteroides thetaiotaomicron was the only species associated with
anti-rotavirus IgA titre. Random forest models poorly classified seroconversion status by both composi-
tion and functional microbiome variables.
Conclusions: RVV immunogenicity is low in this rural Zimbabwean setting, however it was not associated
with the composition or function of the early-life gut microbiome in this study. Further research is war-
ranted to examine the mechanisms of poor oral RVV efficacy in low-income countries.
 2021 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Rotavirus is the leading cause of diarrheal morbidity and mor-
tality in children [1]. Although several oral rotavirus vaccines
(RVV) are currently available globally, their efficacy varies substan-
tially by population, limiting their impact [2]. Large clinical studies
show RVV efficacy of 85–98% against severe rotavirus gastroenteri-
tis in high-income settings [3,4], compared to only 48% and 39% in
R.C. Robertson, J.A. Church, T.J. Edens et al. Vaccine 39 (2021) 5391–5400South Asia [5] and sub-Saharan Africa [6], respectively. The
reasons for poor oral vaccine efficacy in low-income populations
remain poorly understood, however intestinal factors may con-
tribute [7–9].
The gut microbiota plays a critical role in the maturation of
early-life immune function and intestinal development [10]. The
composition of the early-life gut microbiota may also influence
susceptibility to viral infections, since antibiotic treatment and
segmented filamentous bacteria both reduce the pathogenicity of
rotavirus in mice [11,12]. Emerging evidence suggests that the
early-life gut microbiota influences oral vaccine responses by mod-
ulating the immune and metabolic environments of the intestine
[13]. In mice, antibiotic treatment impairs vaccine responses, an
effect that is reversed following restoration of the microbiota
[14]. In adults, narrow-spectrum antibiotics did not alter absolute
anti-RV IgA titres following RVV, but did lead to a higher propor-
tion of individuals displaying short-term IgA ‘‘boosting” (defined
as a  2-fold rise in anti-RV titre 7 days post-vaccination) com-
pared with placebo or broad-spectrum antibiotics [15]. Observa-
tional evidence from children in low-income settings has shown
no consistent association between the fecal microbiota and RVV
efficacy in India [16], while RVV immunogenicity was associated
with fecal microbiota composition in cohorts in Pakistan [17] and
Ghana [18]. In these settings, RVV seroconverters compared to
non-seroconverters displayed a fecal microbiota more similar to
infants from a high-income setting.
We recently reported outcomes of a cluster-randomized trial of
improved water, sanitation and hygiene (WASH) in rural Zim-
babwe [19]. Among a subset of infants in whom anti-rotavirus
IgA titres were measured, only 24% infants seroconverted following
oral RVV administration. However, the WASH intervention signifi-
cantly increased RVV seroconversion by 50% (19.6% in non-WASH
arm versus 30.3% in the WASH arm) [20]. We hypothesised that
the WASH intervention had reduced the burden of enteropatho-
gens in these infants, thereby improving RVV immunogenicity.
However, the WASH intervention had no effect on enteropathogen
carriage [21] and enteropathogen burden was not associated with
RVV immunogenicity [22]. In this follow-on study, we explore
whether alterations in the composition of the fecal microbiome
are associated with RVV immunogenicity, by conducting whole
metagenome shotgun sequencing of stool samples from infants
around the time of RVV. Here we report on (i) the composition
and function of the early-life fecal microbiome in this rural LMIC
setting and (ii) its association with RVV immunogenicity.2. Materials and methods
2.1. Study population
We present a sub-study of the Sanitation Hygiene Infant Nutri-
tion Efficacy (SHINE) trial [19], a 2  2 factorial cluster-randomized
trial assessing the independent and combined effects of improved
WASH and improved infant and young child feeding (IYCF) on
stunting and anaemia (NCT01824940). Briefly, 5280 pregnant
women in rural Zimbabwe were enrolled and cluster-randomized
to standard-of-care, IYCF, WASH or combined IYCF + WASH, and
children were followed up until 18 months of age. 1169 HIV-
unexposed children were enrolled in a sub-study of the SHINE trial
which involved longitudinal specimen collection (including plasma
and stool) at 1, 3, 6, 12 and 18 months of age at scheduled study
visits in participants’ homes [23]. Sterile collection tubes were pro-
vided to mothers, who collected stool samples from their infants
on the day of the study visit. Blood samples were collected from
infants by trained nurses. Samples were placed in cool boxes
immediately upon collection by study nurses and transported by5392motorbike to field laboratories where they were aliquoted and
stored at 80 C within 6 h of collection, before subsequent trans-
port to the central laboratory in Harare for ongoing storage at
80 C. Stool samples were subsequently shipped on dry ice from
Harare to the British Columbia Centre for Disease Control, Vancou-
ver, Canada to undergo DNA extraction and metagenomics
sequencing. A cold chain was maintained throughout and no
freeze–thaw cycles occurred between initial freezing and DNA
extraction. 158 infants with available plasma samples, oral rota-
virus vaccine records and stool samples collected within 30 days
of either vaccine dose were selected for analysis in this study.
The SHINE trial was approved by the Medical Research Council of
Zimbabwe and the Johns Hopkins Bloomberg School of Public
Health Committee on Human Research. Written informed consent
was obtained from all caregivers before enrolment in the trial.
2.2. Sub-study population
For this study, infants were selected from the existing SHINE
cohort if they had at least one available plasma sample collected
post-rotavirus vaccination and an available stool sample collected
at either the 1 or 3-month visits, as per previous analyses [22]. All
stool samples were non-diarrheal. We permitted a 30-day window
of stool collection pre- or post-vaccination (either RVV dose). This
approach was conducted for two reasons: (i) RVV shedding, a
proxy for viral vaccine replication, peaks in the first days after
either dose [24] but has been recorded up to 84 days post vaccina-
tion [25]. Furthermore, IgA typically appears in blood and stool 7–
28 days after rotavirus infection or vaccination suggesting that this
is a dynamic period of immune induction [26]. We therefore
hypothesized that the fecal microbiome soon before, during or
after vaccination may influence RVV immunogenicity; (ii) We pre-
viously used this 30-day approach to study the association
between enteropathogens and RVV immunogenicity [22], thereby
allowing us to conduct a consistent analytical approach of the
intestinal milieu and RVV immunogenicity. In order to assess the
effect of this chosen 30-day time-window around vaccination, we
conducted two sensitivity analyses: first, employing a restricted
time-window to include those collected prior to 43 days of age
(median age of sample collection), all of which were collected prior
to first RVV dose; and second, restricting to samples collected
within 14-days pre or post-RVV. Infants were excluded if they
did not have vaccination data recorded or had not received at least
one dose of RVV. If more than one sample was available per child,
the stool sample collected closest to the first dose of RVV was cho-
sen for analysis. 67 samples meeting these criteria had metage-
nomic sequencing data already available as part of a larger
analysis of the gut microbiome of infants from the SHINE cohort
(unpublished data). A further 91 samples from the SHINE stool bio-
bank meeting the selection criteria for this study were included,
leading to a total of 158 participants in the final analysis. This final
subset was based on the number of participants with available
stool, plasma and RVV immunogenicity data, and is similar to pre-
viously published sample sizes [16–18]. Participants included in
this sub-study were representative of the larger SHINE cohort
(Table S1). All samples were processed in an identical manner.
Baseline household data and infant morbidity data were
recorded by questionnaire and daily morbidity diaries at each visit.
Infant diarrhea was defined as any episode of diarrhea recorded
prior to RVV dose 1 (either in 7-day recall via questionnaire or in
the daily morbidity diary provided to mothers). Data on antibiotic
usage was recorded in SHINE study by maternal recall (14-day
recall), however this data was considered of low quality, partly
due to the potential for mis-identification of medication. Only 5
of 158 participants included in this study recorded antibiotic
usage.
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Oral monovalent RVV (RotarixTM; GSK Biologicals) was intro-
duced as part of the Zimbabwean Expanded Programme on Immuni-
sation in May 2014 and was administered to infants at 6 and
10 weeks of age concurrently with oral polio vaccine. National vac-
cination coverage in 2015–2016 was 87–91% [27]. Vaccination was
undertaken at local clinics as part of routine national vaccination
programmes and was not overseen by the SHINE trial team. Vaccina-
tion dates were recorded by SHINE study staff by reviewing child
health cards. Plasma anti–rotavirus immunoglobulin A (IgA) was
measured on stored plasma samples collected at 1 and 3 months
of age by enzyme-linked immunosorbent assay (ELISA) using meth-
ods previously described [28]. The primary outcome was RVV sero-
conversion, defined as a post-vaccine plasma concentration of
anti–rotavirus IgA  20 U/mL in infants who were seronegative
(<20 U/mL) pre-vaccination [29]. Secondary outcomes included
anti–rotavirus IgA titre and RVV seropositivity, defined as a post-
vaccine titre  20 U/mL, regardless of pre-vaccine titre. All 3 out-
comes were considered in participants with at least 1 vaccine dose.
We refer to these outcomes collectively as RVV immunogenicity.
2.4. Stool metagenome sequencing
DNAwas extracted from ~200 mg stool using the Qiagen Power-
Soil Kit with bead beating. DNA quality was confirmed by spec-
trophotometry (SimpliNano) and quantified by fluorometry
(Qubit). 1 mg DNA was used as an input for sequencing library
preparation following the Illumina TruSeq PCR-free library prepa-
ration protocol, using custom end-repair, adenylation and ligation
enzyme premixes (New England BioLabs). Constructed libraries
were assessed for quality of concentration (qPCR) and size (Tapes-
tation 2200) prior to pooling. 48 barcoded samples were pooled at
random in each sequencing run. Positive controls (ZymoBIOMICS)
and DNA-free negative controls were included through all steps
including DNA extraction and library preparation. One negative
control was included in each sequencing pool. Duplicate samples
were also run across different sequencing pools to monitor
sequencing batch effects. Whole metagenome sequencing was per-
formed with 125-nucleotide paired-end reads using either the Illu-
mina HiSeq 2500 or HiSeqX platforms at Canada’s Michael Smith
Genome Sciences Centre, Vancouver, Canada.
KneadDatawas used with default settings to remove short reads
(<60 bp), duplicate reads, human and other non-microbial reads
and to trim off adapters. Filtered sequencing reads were processed
through the MetaPhlAn3 pipeline [30] with default settings to gen-
erate compositional data. HUMAnN3was used with default settings
using the UniRef90 database to generate functional annotations
(enzyme commission (EC) annotations and pathways) [31]. Com-
positional and functional data were filtered using a minimum
threshold of > 0.1% and > 0.0001% relative abundance, respectively.
Taxa were included in the analyses if present at a minimum
threshold of 5% prevalence within the entire dataset.
A median of 8.1 ± 3.0 million quality filtered reads were pro-
duced per sample. Sixteen negative controls were also sequenced
with mean 734 quality-filtered reads (range = 149 to 11,432,
SD = 3462). Following filtering of annotatable reads, 139 species
were included in the final analysis, of which 4 were classified as
co-abundance gene groups metagenomic assemblies (CAGs) for
which no culture-derived representative exists.
2.5. Statistical analyses
All data were analysed using R (v.4.0.2). Beta-diversity was esti-
mated using the Bray-Curtis dissimilarity index. Alpha diversity
was assessed using the Shannon index and the number of observed5393species. Differential abundance analysis was performed by Wil-
coxon rank sum test and Analysis of Composition of Microbiomes
(ANCOM) [32]. Random forest machine learning models were per-
formed using the randomForest package (SIAMCAT package [33])
in which five-fold cross-validation was performed with 100 itera-
tions. Microbiome regression analyses were performed using the
MaAsLin2 package. Seven covariates were chosen for adjustment
in regression models and included age at stool sample collection,
birthweight, exclusive breastfeeding status (recorded at 3 months
old), sex, WASH randomized trial arm, delivery mode and length-
for-age Z-score (LAZ) around time of vaccination. These covariates
were chosen based on biological plausibility and previous evidence
of their independent influence on RVV immunogenicity in the
same cohort [34]. Multiple comparisons were tested using
Benjamini-Hochberg false discovery rate (FDR; q-value < 0.05).3. Results
3.1. Study cohort
Among 5280 women enrolled in the SHINE trial, there were
3989 live-born, HIV-unexposed infants. Of these, 882 children
had RVV immunogenicity measured and 158 of these with stool
samples collected within 30 days of either vaccine dose underwent
whole metagenome sequencing. Table 1 outlines the primary char-
acteristics of the 158 participants in this analysis. Of these 158 par-
ticipants, 115 had seroconversion data available as a primary
outcome (n = 81 non-seroconverters, n = 34 seroconverters;
Fig. 1a), whilst secondary outcomes (seropositivity status and IgA
titres) were available for all 158 infants (n = 113 seronegative,
n = 45 seropositive). 154 of 158 (97.5%) infants had documented
receipt of both RVV doses. Seroconverters received their first dose
a median of 2 days (P = 0.002) and their second dose a median of
4.5 days (P = 0.037) prior to non-seroconverters. 15/34 (44.1%) of
seroconverters and 31/81 (38.3%) of non-seroconverters were
female (P > 0.05). The baseline characteristics of the 158 included
infants were largely representative of the larger SHINE cohort
(Table S1).
The median age at RVV was 44 days [interquartile range (IQR):
42–49] for the first dose and 77 days (IQR: 72–88) for the second
dose. The median age at pre-vaccine RV IgA titre measurement
was 37 days (IQR: 34–45) and 102 days (IQR: 98–116) for post-
vaccine titre. Themedian age at stool sample collectionwas 43 days
(IQR: 35–68), corresponding to a median of 4 days (IQR: +11 to
22) before the first RVV dose (Fig. 1b). To test for and account
for age-associated changes in microbiota composition, analyses
were also split by early stool samples (42 days of age), all of
which were collected prior to the first RVV dose, and late stool
samples (>42 days of age).3.2. Microbiome alpha and beta diversity associations with RVV
immunogenicity
PERMANOVA analysis identified a small but significant differ-
ence in beta diversity as measured by Bray-Curtis distances by
seroconversion status (P = 0.035; R2 = 0.014; Fig. 2a), however this
was largely explained by data dispersion (homogeneity of disper-
sion test; P = 0.035). When split by median age of sample collection
(43 days), there was a significant difference in Bray-Curtis dis-
tances between early and late samples (P < 0.001; R2 = 0.025;
Fig. 2b). No significant difference was observed between infants
randomized to WASH or non-WASH trial arms (Fig. S1a).
In sensitivity analyses, when restricting to samples collected
within 14 days of either vaccine dose (n = 62 non-seroconverters,
n = 28 seroconverters), there was a significant difference in Bray-
Table 1
Baseline characteristics of the seroconversion and seropositivity cohorts
Seroconversion Seropositivity
Non-seroconverters Seroconverters P value Seronegative Seropositive P value
N = 81 N = 34 N = 113 N = 45
Female, % 38.3 44.1 40.7 51.1
Birthweight, kg (sd) 3.17 (0.48) 3.06 (0.55) 0.303 3.11 (0.49) 3.06 (0.50) 0.564
Low birthweight1, % 4.94 11.8 7.96 8.89
Vaginal delivery, % 96.3 97.1 95.6 95.6
Institutional delivery, % 91.2 94.1 93.8 95.6
Exclusively breastfed (at month 3), % 90 97.1 90.1 95.5
Concurent OPV vaccination, % 95.7 93.8 96.5 92.1
Age at stool sample, days [IQR] 38.0 [34.0; 66.0] 37.0 [33.2;40.8] 0.222 45.0 [35.0; 78.0] 38.0 [34.0; 59.0] 0.034
Age at first RV dose, days [IQR] 46.0 [43.0; 54.0] 44.0 [42.0;45.0] 0.002 45.0 [42.0; 50.0] 44.0 [42.0; 45.0] 0.019
Age at second RV dose, days [IQR] 81.5 [74.2; 99.5] 77.0 [75.0;81.8] 0.037 78.0 [72.0; 93.0] 77.0 [74.8; 83.2] 0.669
LAZ at 1 month visit [IQR] 0.88 (1.09) 0.80 (1.43) 0.783 1.00 (1.19) 0.73 (1.33) 0.267
LAZ at 3 month visit (sd) 0.90 (1.07) 0.84 (1.19) 0.786 0.94 (1.13) 0.88 (1.25) 0.791
SHINE trial arm2, %
SOC 29.6 17.6 30.1 17.8
IYCF 28.4 35.3 28.3 31.1
WASH 19.8 17.6 21.2 20
WASH + IYCF 22.2 29.4 20.4 31.1
Born in RV season3, % 33.3 44.1 29.2 37.8
Household size 5 [4; 6] 5 [4; 6] 0.126 5.00 [4; 6] 5.00 [4; 6] 0.298
Mother age at baseline, years (sd) 27.9 (5.77) 27.3 (6.09) 0.659 27.6 (5.96) 27.2 (6.50) 0.787
Mother height at baseline, cm (sd) 161 (6.17) 161 (5.95) 0.983 160 (5.90) 161 (6.24) 0.722
Both RVV doses received, % 96.3 100 97.3 97.8
Diarrhea pre-RVV4, % 11.2 11.8 10.7 11.1
1 Low birthweight calculated as < 2500 g.
2 SOC, Standard of Care; IYCF, Infant and Young Child Feeding; WASH, Water, Sanitation and Hygeine; WASH + IYCF, combined WASH and IYCF arm.
3 RV season in Zimbabwe was defined as 1st April-31st July based on national surveillance data.
4 Defined as any episode of diarrhea recorded pre-RVV (either in 7-day recall via questionnaire or in the daily morbidity diary provided to mothers).
Fig 1. Study flow. (a) Flow diagram of stool samples included in the analysis originating from the SHINE trial. (b) Timing of stool samples included in the analysis and
associated RVV doses.
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Fig. 2. Beta diversity analysis by seroconversion status and early vs late samples. Principal coordinates analysis (PCoA) and associated Bray-Curtis distances to assess beta
diversity of seroconversion status (a) and early vs late samples (b) as assessed using PERMANOVA analysis.
R.C. Robertson, J.A. Church, T.J. Edens et al. Vaccine 39 (2021) 5391–5400Curtis distances by seroconversion status (P = 0.011; R2 = 0.022;
Fig. S1b), which was partly explained by data dispersion
(P = 0.03). However, there was no significant difference in Bray-
Curtis distances by seroconversion status when restricted to early
samples (42 days of age; n = 79 samples; P = 0.061; R2 = 0.024). In
analyses of secondary outcomes, beta diversity differed signifi-
cantly by seropositivity status (P = 0.008; R2 = 0.012; Fig. S1c) in
the total dataset, which was not explained by dispersion
(P = 0.067), but not when restricted to samples collected
before  42 days of age (P = 0.113; R2 = 0.019).
Alpha diversity, as measured by the Shannon index and number
of observed species, did not significantly differ by seroconversion
(Wilcoxon test: P = 0.366 & P = 0.282 respectively; Fig. 3a) and
was not associated with anti-rotavirus IgA titre in simple linear
regression (P = 0.339; Fig. 3b). There were significant differences
in alpha diversity between early and late samples (P = 0.008).
In sensitivity analyses, alpha diversity also did not differ by
seroconversion status or seropositivity status when restricted to
early samples (P = 0.327 and P = 0.269, respectively) or when
restricted to stool samples collected within 14 days of either RVV
dose (data not shown). There was also no significant difference
in alpha diversity by seropositivity status (P = 0.153; Fig. S2a-b)
or by randomized WASH arms (Fig. S2c).3.3. Infant microbiome taxonomic composition and association with
RVV immunogenicity
At the phylum level, samples were dominated by Actinobacteria
(Fig. 3c). Bifidobacterium longum was the most abundant species in
the entire dataset comprising a median 23% relative abundance,
ranging from 0% to 97% across all samples. Escherichia coli, Collin-
sella aerofaciens, B ifidobacterium bifidum and Bifidobacterium pseu-5395docatenulanum were the next most highly abundant across all
datasets. Differential abundance analysis showed no significant
differences in relative abundances of any taxa by seroconversion
status (Wilcoxon ranked sum test, q > 0.05; Fig. 3d). This negative
result was confirmed by the more stringent ANCOM model, which
included covariate adjustment for age at stool sample collection,
birthweight, exclusive breastfeeding status, sex, trial arm, delivery
mode and LAZ around vaccination. Six species were significantly
differentially abundant between early and late samples (Wilcoxon,
q < 0.05: B. longum, Streptococcus mitis, Bacteroides ovatus, Collin-
sella aerofaciens, Staphylococcus hominis, Streptococcus pneumoniae;
Fig. 4a and S2e) which was confirmed by ANCOM following
covariate adjustment. In analysis of secondary outcomes, no taxa
were significantly different by seropositivity status (Fig. S2f). In
sensitivity analyses, when restricted to early samples or
restricted to samples collected within 14 days of either vaccine
dose, no taxa were significantly differentially abundant when com-
pared by seroconversion or seropositivity statuses. Collinsella aero-
faciens was the only species significantly different in relative
abundance between WASH and non-WASH infants in this sub-
cohort, displaying significantly lower relative abundance in WASH
infants (Fig. S2g).
Random forest models were also applied to the datasets to test
whether microbiome features could predict seroconversion and
age. Early and late samples were strongly classified by the random
forest model (receiver operating curve area under the curve (AUC)
0.758; Fig. 4b). Random forest regression of age produced moder-
ately strong models (P = 0.001; R2 = 0.152; 14% explained varia-
tion). However, random forest poorly classified seroconversion
status (AUC 0.589; Fig. 4c). In analysis of other secondary out-
comes, random forest also poorly classified seropositivity (AUC
0.564; Fig. S3a) and WASH trial arm (AUC 0.5; Fig. S3b).
Fig. 3. Alpha diversity and taxonomic composition. (a) Alpha diversity, as assessed using the Shannon index and number of observed species, between serconverters and non-
seroconverters. (b) Associations between alpha diversity, age at stool sample collection and RV IgA titre. (c) Phylum composition of entire dataset. (d) Species composition in
seroconverters vs non-seroconverters.
Fig. 4. Differential abundance analysis and machine learning models of taxonomic composition. (a) Species that differ significantly in relative abundance between early
(42 days of age) and late (>42 days of age) samples as assessed by Wilcoxon ranked sum test (q value < 0.05). Random forest machine learning classification model of (a)
early vs late samples and (b) seroconverters vs non-seroconverters using all microbiome species.
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Fig. 5. Functional metagenomic analysis. Enzyme commission annotations that differ significantly in relative abundance between early vs late samples (Wilcoxon rank sum
test; q value < 0.05; top 20 ECs shown as ranked by q-value).
R.C. Robertson, J.A. Church, T.J. Edens et al. Vaccine 39 (2021) 5391–5400Regression models were built (MaAsLin2) to identify associa-
tions between fecal microbial taxa and age or vaccine titres. Fol-
lowing FDR correction and adjustment for covariates, Bacteroides
thetaiotaomicronwas the only species associated with IgA titre, dis-
playing a significant positive correlation (Fig. S4a; q = 0.008). This
effect held in sensitivity analyses using samples collected within
14 days of either vaccine dose (q = 0.053) whilst also indicating
that Slackia isoflavoniconvertenswas also positively associated with
IgA titre in the restricted sensitivity dataset (Fig. S4b; q = 0.049).3.4. Infant microbiome functional composition and association with
RVV immunogenicity
Metagenomic data were also analysed to assess microbiome
functional pathways associated with age and RVV responses. Wil-
coxon tests identified no functional pathway or EC that differed
significantly by seroconversion status. Random forest models of
microbiome functional pathways also poorly classified seroconver-
sion status. Two metagenomic pathways (PWY  5994: palmitate
biosynthesis I (animals and fungi and PWY 1042: glycolysis IV (plant
cytosol)) and 153 ECs were differentially abundant between early
and late samples (Fig. 5). Random forest models performed moder-
ately well in classifying early and late samples based on metage-
nomic pathways (AUC 0.641; Fig. S3c). No EC or metagenomic
pathway was significantly associated with IgA titre. In sensitivity
analyses of early samples or those collected within 14 days of
either vaccine dose, no EC or metagenomic pathway was associ-
ated with seroconversion and random forest classification was
poor. No significant functional differences were observed by
seropositivity status.53974. Discussion
Here, we report on the stool metagenomes of 158
infants < 6 months of age from a rural Zimbabwean birth cohort
and their association with RVV immunogenicity. Similar to other
low-income settings, RVV was poorly immunogenic in this cohort
(24% seroconversion). The reasons for this are unclear, but dynamic
changes in the microbiota at this age may influence mucosal
immune responses to an oral vaccine. However, we do not find dis-
tinct fecal microbiome signatures that distinguish RVV serocon-
verters from non-seroconverters. Hence, poor vaccine
seroconversion in this population does not appear to be explained
by the fecal microbiome.
A handful of previous studies have demonstrated conflicting
evidence for the association between the infant fecal microbiome
and oral RVV efficacy. Most recently, a large multi-country study
reported that gut microbiota alpha diversity, as assessed using
16S amplicon sequencing, was negatively correlated with RVV
immunogenicity in Malawi and India, however no differences were
observed in taxonomic composition between seroconverters and
non-seroconverters [35]. A previous analysis of 170 infants in
south India failed to find an association between the commensal
infant fecal microbiome and RVV seroconversion [16]. In the same
study, however, RVV seroconverters were more likely to harbour at
least one bacterial enteropathogen than non-seroconverters. Con-
versely, two separate studies in Ghana (n = 20) [18] and Pakistan
(n = 78) [17], employing HITChip microarrays rather than next-
generation sequencing, both demonstrated that the fecal micro-
biome of RVV seroconverters differed significantly to non-
seroconverters. Both of these studies also reported that the fecal
R.C. Robertson, J.A. Church, T.J. Edens et al. Vaccine 39 (2021) 5391–5400microbiome of seroconverters versus non-seroconverters were
more similar to infants from a high-income setting in the Nether-
lands. However, the taxa associated with RVV seroconversion dif-
fered between countries. Higher relative abundances of
Clostridium cluster XI and Proteobacteria were associated with
seroconversion in Pakistan, whilst higher Streptococcus bovis and
lower Bacteroidetes were associated with seroconversion in
Ghana.
Due to the methodological differences in sequencing and the
geographic differences in the cohorts, it is difficult to draw compar-
isons with these previous studies. Geographic setting has a major
influence on gut microbiome composition and inter-individual
variation between children across geographical settings is greater
than in adults [36]. The results presented here, using gold-
standard metagenome sequencing, failed to find a clear infant
microbiome signature that distinguished RVV seroconverters from
non-seroconverters. Previous evidence shows that the strongest
contributor to infant gut microbiome composition in early-life is
exclusivity of breastfeeding [37], which was extremely high in this
cohort (>80%) due to study interventions designed to promote
early and exclusive breastfeeding. Hence, any gut microbiome sig-
natures associated with RVV seroconversion may be outweighed
by the influence of breastfeeding. Other environmental factors in
early-life can influence gut microbiome composition, including
delivery mode, malnutrition and sex. An in-depth analysis of the
influence of each of these environmental factors on gut micro-
biome composition in this cohort was beyond the scope of this cur-
rent study. However these variables were all included as covariates
in each of the models reported here, suggesting that the null asso-
ciation between the gut microbiome and oral rotavirus vaccine
efficacy reported here was not influenced by any of these potential
confounders.
We recently reported that enteropathogen carriage was not
associated with RVV seroconversion in this cohort [22]. The results
presented here extend these observations by showing that neither
commensal nor pathogenic enteric microbes were associated with
RVV seroconversion. Oral RVV is taken up in the small intestine,
whereas the microbiome and enteropathogen carriage measured
in stool largely reflect the colonic intestinal environment. This
may partly explain why we observed no association between the
stool microbiota and RVV seroconversion in this cohort. Future
studies examining the small intestinal microbiota may provide
greater insight into the potential interaction between the com-
mensal gut microbiome and oral vaccines. It remains unclear what
biological factors contribute to poor RVV immunogenicity in low-
income settings. Improved WASH enhanced RVV immunogenicity
by 50% in this cohort [20], yet had no impact on enteropathogen
carriage [21] or diarrhea [19]. In this subset of infants, WASH sim-
ilarly had no significant impact on the early-life fecal microbiome,
suggesting that the effect of WASH on RVV immunogenicity is not
driven through the fecal microbiome. Hence, the causal pathway
linking improved WASH with improved RVV seroconversion
remains unexplained and complex.
This study benefited from a well-characterized cohort of infants
from a large, community-based, cluster randomized trial. RVV
seroconversion, measured in a subset of infants, was 23.7%,
demonstrating its suitability as a representative infant population
with low RVV immunogenicity. Within this subgroup, we have pre-
viously investigated and reported on a number of environmental
factors associated with RVV seroconversion including enteropatho-
gen carriage, WASH, household factors, birthweight and nutritional
status [20,22,34]. Hence the data presented here, albeit negative,
add to the evidence base of RVV immunogenicity in a unique,
well-characterised cohort by contributing unique insight into the
intestinal milieu and its association with oral vaccine efficacy.
We employed whole metagenome shotgun sequencing, which5398has not previously been extensively conducted in low-income set-
tings, allowing us to examine both taxonomic and functional
microbiome variables in relation to RVV seroconversion. It is also
one of the very few high-resolution, metagenomic datasets from
infants in a rural, non-industrialized setting.
The study is limited by its relatively small sample size, which is
partly due to the low seroconversion rate in this population, the
number of stool samples available for sequencing analysis and
the criteria of sample selection within a 30-day time-window close
to vaccination. This arbitrary time-window was based on the
hypothesis that the intestinal environment around the time of vac-
cination may alter vaccine efficacy. RVV shedding, a proxy for viral
vaccine replication, peaks in the first days after either dose [24] but
has been recorded up to 84 days post vaccination [25]. Further-
more, IgA typically appears in blood and stool 7–28 days after rota-
virus infection or vaccination, suggesting that this is a dynamic
period of immune induction [26]. We therefore hypothesized that
the infant gut microbiome in the days/weeks immediately before
or after vaccination, during viral vaccine replication, may influence
subsequent immunogenicity. Furthermore, this approach comple-
mented our previous analyses of enteropathogens and RVV
immunogenicity in this same cohort using the same cut-off around
vaccination, thereby providing us with a consistent analytical
approach with which to investigate the intestinal milieu and RVV
immunogenicity [22].
The study is limited, however, by this sampling approach. The
relatively wide dispersion of ages and time-windows between vac-
cination and stool sample collection may lead to confounding
effects of age on any potential gut microbiome associations, which
must be considered in the interpretation of these results. To miti-
gate this, we adjusted for age in all regression models and also per-
formed sensitivity analyses using a restricted 14-day time window
and analysing a subset of ‘early’ samples collected before 43 days
of age (median age of sample set), all of which were collected prior
to vaccination. Sensitivity analyses using both of these restricted
datasets also did not identify any comprehensive associations
between the fecal microbiota and RVV immunogenicity, whereby
no differences were observed in alpha diversity or the relative
abundance of any individual species, gene or metagenomic path-
way between seroconverters and non-seroconverters. Despite
these approaches to account for the dispersion of ages and times
between stool samples and vaccination, this analytical approach
may still limit our ability to identify true associations between
the gut microbiome and RVV seroconversion.
Secondly, the outcomes assessed in this study (seroconversion
and seropositivity) may not be accurate correlates of vaccine pro-
tection against rotavirus infection [38]. We focussed on serocon-
version as a primary outcome as this depends on both pre and
post-vaccine titres and also included seropositivity as a secondary
analysis. However, as we and others have reported [34], natural
rotavirus infection prior to vaccination may confound IgA titres
which limits both seroconversion and seropositivity in particular
as an outcome. Hence, RV IgA titres are an imperfect correlate of
vaccine protection and future studies incorporating other corre-
lates, such as vaccine virus replication, are warranted. Thirdly,
the SHINE study was not a vaccine trial and hence the study team
had no control over the administration, dosing or timing of vacci-
nations, which were conducted independently of the SHINE trial
as part of the Zimbabwean Expanded Programme on Immunisa-
tion. We relied on vaccine data transcribed from participant health
cards. The timing of stool collection, and therefore microbiome
assessment, was independent of vaccine administration. Addition-
ally, 4/158 (2.5%) participants had documented receipt of only 1
RVV dose. However, we have previously reported in the SHINE
study that seroconversion rates in those reporting  1-dose of
RVV were similar to those with 2 reported RVV doses, and the ben-
R.C. Robertson, J.A. Church, T.J. Edens et al. Vaccine 39 (2021) 5391–5400eficial effects of WASH on these seroconversion rates were the
same regardless of 1 or 2 doses [20,34]. Finally, due to the difficul-
ties in obtaining viral reads from stool metagenomic data, we were
unable to determine the impact of enteroviruses on RVV serocon-
version, which has been hypothesized previously to be associated
with RVV immunogenicity [16]. Specific analysis of the infant vir-
ome may shed more light on RVV underperformance.
In conclusion, we found no clear stool microbiome signature
associated with oral RVV immunogenicity in rural Zimbabwean
infants. Future studies incorporating protection from rotavirus dis-
ease, are warranted.
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